Skip to main content
U.S. flag

An official website of the United States government

This site is currently in beta, and your feedback is helping shape its ongoing development.

Return to search results

Ledipasvir and sofosbuvir

Published by U.S. Food and Drug Administration | U.S. Department of Health & Human Services | Metadata Last Checked: February 18, 2026 | Last Modified: 2025-03-17
Harvoni is a prescription medication by Gilead Sciences containing ledipasvir and sofosbuvir, used to treat chronic hepatitis C virus (HCV) infection in adults. It comes as oral pellets in strengths like 45 mg ledipasvir and 200 mg sofosbuvir per packet, taken once daily for 8-12 weeks depending on HCV genotype. It works by inhibiting HCV replication. Consult a doctor for proper use and side effects. This information was generated using AI and is provided for informational and research purposes only.

Find Related Datasets

Click any tag below to search for similar datasets

data.gov

An official website of the GSA's Technology Transformation Services

Looking for U.S. government information and services?
Visit USA.gov